以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 证券之星消息，2月5日南向资金减持70.5万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金增 持的有1天，累计净增持126.48万股。近20个交易日中，获南向资金增持的有12天，累计净增持759.36万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7299.06万股，占公司已发行普通股的5.53%。 ...

| 笔克远东(00752) | 2.900 | 2.960 | 1.37% | | --- | --- | --- | --- | | 东吴水泥(00695) | 9.580 | 9.990 | 1.32% | | 天虹国际集团(02678) | 5.720 | 5.720 | 1.24% | | 渣打集团(02888) | 204.200 | 204.400 | 1.19% | | 明梁控股(08152) | 0.088 | 0.088 | 1.15% | | 电能实业(00006) | 61.750 | 62.100 | 1.14% | | 太古股份公司Ａ(00019) | 77.550 | 77.600 | 1.11% | | 湾区发展(00737) | 1.900 | 1.920 | 1.05% | | 春城热力(01853) | 2.000 | 2.000 | 1.01% | | 硬蛋创新(00400) | 4.050 | 4.100 | 0.99% | | 健康１６０(02656) | 87.050 | 88.400 | 0.91% | | Ａ南方人民币(03122) | 189.800 | 18 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02609 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,318,466,823 | | | | 1,318,466,823 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,318,466,823 | | 0 | | 1,318,466,823 | 公司名稱: 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2026-02-02 | 7149.78万 | -3.78万 | -0.05% | | 2026-01-30 | 7153.56万 | -19.02万 | -0.27% | | 2026-01-29 | 7172.58万 | 2.04万 | 0.03% | | 2026-01-28 | 7170.54万 | 22.02万 | 0.31% | | 2026-01-27 | 7148.52万 | -64.80万 | -0.90% | 证券之星消息，2月2日南向资金减持3.78万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金减 持的有3天，累计净减持63.54万股。近20个交易日中，获南向资金增持的有13天，累计净增持834.6万 股。截至目前，南向资金持有佰泽医疗（02609.HK）7149.78万股，占公司已发行普通股的5.41%。 佰泽医疗集团是一家 ...

在传统医疗体系中，患者出院往往意味着专业医疗支持的阶段性"断点"。 尤其在肿瘤领域，术后康 复、临床级营养及心理支持、复发预警长期游离于医院体系之外，形成了家庭与机构间的"服务断层"。 这一结构性缺失，正成为制约临床效果与患者生命质量的核心变量。 随着肿瘤被重新定义为可长期管理的慢性疾病，行业开始审视一个本质命题：当患者的生命周期延长， 医疗服务是否仍应止步于物理围墙之内？在这一背景下，佰泽医疗（02609.HK）将H@H（Hospital At Home）作为其全周期战略的重要实践，推动医疗服务从"院内集中"向"连续管理"延伸。 佰泽医疗在这一方向上的探索，正是将H@H纳入整体数字健康体系之中，通过统一的数据平台与业务 系统，连接院内诊疗、康复管理与家庭场景，使医疗能力得以在不同阶段、不同空间中连续发挥作用。 结语 ：医疗服务边界正在被重新书写 H@H的出现，折射出肿瘤医疗服务价值取向的变化。行业关注点正在从单次治疗效果，转向客户长期 生活质量与生命体验。这一转向并非情怀驱动，而是由疾病特征变化、人口结构调整与患者需求升级共 同推动的必然结果。 这不仅是一次商业模式的创新，更是一场关于生命尊严的务实实践：让 ...

佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 证券之星消息，1月28日南向资金增持22.02万股佰泽医疗（02609.HK）。近5个交易日中，获南向资金 增持的有4天，累计净增持320.94万股。近20个交易日中，获南向资金增持的有14天，累计净增持882.42 万股。截至目前，南向资金持有佰泽医疗（02609.HK）7170.54万股，占公司已发行普通股的5.42%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - Baize Medical has officially launched a new strategy that transforms its role from a "disease treatment provider" to a "full-cycle health manager," focusing on a systematic and replicable medical practice across eight key stages of cancer care, leveraging an AI-ready continuous medical service platform [1] Group 1: Redefining Service Boundaries - Baize Medical is redefining the scope of cancer care, expanding its services from merely treating patients to providing comprehensive health management for all individuals seeking health [2] - The service continuum now includes preventive interventions for healthy populations and long-term follow-up for recovering patients, creating a health protection ecosystem that respects the essence of life [2] Group 2: Constructing a Measurable Health Journey - The "full-cycle management" is embodied in eight service stages: prevention, screening, diagnosis, treatment, rehabilitation, management, connection, and companionship, forming a complete service loop [3] - The innovative stages of "management," "connection," and "companionship" are integrated into the standardized service system, marking a significant breakthrough in service elevation [3] Group 3: Implementation Mechanisms - To ensure the execution of its ambitious blueprint, Baize Medical focuses on five key capabilities: organizational restructuring, internal control compliance, performance incentives, digital infrastructure, and cultural embedding, aiming to enhance operational efficiency and service quality by 2026 [5] - The company has established a dual-driven mechanism of "intelligent information systems" and "standardized management systems" to overcome challenges in scaling operations within the private healthcare sector [5] Group 4: Advancing Healthcare Delivery - Baize Medical's H@H (Hospital At Home) model extends medical capabilities beyond physical boundaries, ensuring that hospital-level professional care is delivered at home through deep integration of standards and intelligence [7] - The implementation of H@H relies on a medical-grade data governance system that ensures data integrity and privacy, supporting high-risk remote medical decisions [7] Group 5: Future Outlook - With a network of eight physical hospitals across five provinces and a proven standardized system, Baize Medical is poised to set a new high-quality benchmark for the transformation of private cancer care in China [8] - The future of healthcare is envisioned as an ecosystem that nurtures hope, blending technological rationality with human warmth to safeguard the dignity and longevity of every life [8]

Group 1 - The core point of the article highlights the recent trading activity of southbound funds in Baize Medical (02609.HK), indicating a reduction of 369,000 shares on January 8, while showing a net increase of 4,179,000 shares over the past five trading days [1] - Over the last 20 trading days, Baize Medical experienced a net increase of 2,540,400 shares from southbound funds, with 11 days of net buying [1] - As of now, southbound funds hold 65,397,000 shares of Baize Medical, representing 4.96% of the company's total issued ordinary shares [1] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [1] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [1] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） 呈交日期: 2026年1月6日 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02609 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,318,466,823 | | | | 1,318,466,823 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 1,318,466,823 | | 0 | | 1,318,466,823 | I. ...

Group 1 - The core index of the Shenzhen-Hong Kong Stock Connect Medical Index (983035) closed at 4400.67 points, down 0.84%, with a trading volume of 9.364 billion yuan and a turnover rate of 0.96% [1] - Among the constituent stocks, 8 stocks increased, with Aidi Te leading with a rise of 3.21%, while 48 stocks decreased, with Baize Medical leading the decline at 6.52% [1] - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 390 million yuan, while retail investors saw a net inflow of 497 million yuan [2] Group 2 - The Shenzhen-Hong Kong Stock Connect Medical Index made adjustments in the last 10 days, adding 2 new stocks to its constituents [2]